We’re excited to share that our CEO, Lake Paul, PhD, is featured alongside leaders from AbbVie, Arvinas, EpiBiologics and SynsoryBio in the latest issue of Genetic Engineering & Biotechnology News exploring innovative approaches to protein degradation therapies!
The article showcases how BioAnalysis and AbbVie are collaborating to understand PROTAC kinetics through advanced Analytical Ultracentrifugation (AUC) while highlighting complementary approaches from other industry pioneers.
“Ultimately, this AUC platform has the potential to speed up the experimental timelines in the targeted protein degrader space while simultaneously reducing cost and labor.” – Lake Paul, PhD, CEO of BioAnalysis
How we’re making a difference:
- Pioneering analytical methods to understand complex protein-protein interactions
- Collaborating with industry leaders to accelerate therapeutic development
- Providing scientific excellence that translates to practical solutions
At BioAnalysis, we combine scientific rigor with client-focused solutions to support the next generation of therapies. Our deep biophysics and mass spectrometry expertise makes us the ideal partner for companies developing cutting-edge therapeutics.
Learn more about our innovative analytical services at
and read the full article at